NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.

Pratt V, McLeod H, Rubinstein W, et al., editors. Medical Genetics Summaries [Internet]. Bethesda (MD): National Center for Biotechnology Information (US); 2012-.

Cover of Medical Genetics Summaries

Medical Genetics Summaries [Internet].

Show details

Azathioprine Therapy and TPMT Genotype

, MD.

Author Information

Created: ; Last Update: May 3, 2016.

Estimated reading time: 9 minutes

Introduction

Azathioprine is an immunosuppressant that belongs to the drug class of thiopurines. It is used in combination with other drugs to prevent kidney transplant rejection and in the management of rheumatoid arthritis when other treatments have not been effective (1). In addition, off-label uses include the treatment of inflammatory bowel disease (2).

Azathioprine is a prodrug that must first be activated to form thioguanine nucleotides (TGNs), the major active metabolites. Thiopurine S-methyltransferase (TPMT) inactivates azathioprine, leaving less parent drug available to form TGNs.

An adverse effect of azathioprine therapy is bone marrow suppression, which can occur in any patient, is dose-dependent, and may be reversed by reducing the dose of azathioprine. However, patients who carry two nonfunctional TPMT alleles universally experience life-threatening myelosuppression when treated with azathioprine, due to high levels of TGNs. Patients who carry one nonfunctional TPMT allele may also be unable to tolerate conventional doses of azathioprine (3, 4).

The FDA recommends TPMT genotyping or phenotyping before starting treatment with azathioprine. This allows patients who are at increased risk for toxicity to be identified and for the starting dose of azathioprine to be reduced, or for an alternative therapy to be used (1).

The Clinical Pharmacogenetics Implementation Consortium (CPIC) has published recommendations for TPMT genotype-based azathioprine dosing. These recommendations include:

Consider an alternate agent or extreme dose reduction of azathioprine for patients with low or deficient TPMT activity. Start at 30-70% of target dose for patients with intermediate enzyme activity (see Table 1) (2-4).

Table 1.

TPMT phenotypes and the therapeutic recommendations for azathioprine therapy, adapted from CPIC

PhenotypePhenotype detailsTPMT
Genotype
Examples of diplotypesTherapeutic recommendations for azathioprine
Homozygous wild-type (“normal”)High enzyme activity.
Found in ~86–97% of patients.
Two or more functional TPMT alleles*1/*1Start with normal starting dose (e.g., 2–3 mg/kg/d) and adjust doses of azathioprine based on disease-specific guidelines.
Allow 2 weeks to reach steady state after each dose adjustment.
HeterozygousIntermediate enzyme activity.
Found in ~3–14% of patients.
One functional TPMT allele plus one nonfunctional TPMT allele*1/*2
*1/*3A
*1/*3B
*1/*3C
*1/*4
If disease treatment normally starts at the “full dose”, consider starting at 30–70% of target dose (e.g., 1–1.5 mg/kg/d), and titrate based on tolerance.
Allow 2–4 weeks to reach steady state after each dose adjustment.
Homozygous variantLow or deficient enzyme activity.
Found in ~1 in 178 to 1~3736 patients.
Two nonfunctional TPMT alleles*3A/*3A
*2/*3A
*3C/*3A
*3C/*4
*3C/*2
*3A/*4
Consider alternative agents. If using azathioprine start with drastically reduced doses (reduce daily dose by 10-fold and dose thrice weekly instead of daily) and adjust doses of azathioprine based on degree of myelosuppression and disease-specific guidelines.
Allow 4–6 weeks to reach steady state after each dose adjustment.
Azathioprine is the likely cause of myelosuppression.

The strength of therapeutic recommendations is “strong” for all phenotypes.
Table is adapted from Relling M.V. et al. Clinical Pharmacogenetics Implementation Consortium guidelines for thiopurine methyltransferase genotype and thiopurine dosing. Clinical pharmacology and therapeutics. 2011;89(3):387–91 (3, 4).

Drug Class: Thiopurines

Thiopurines are used as anticancer agents and as immunosuppressants in inflammatory bowel disease, rheumatoid arthritis, and other autoimmune conditions. Three thiopurines are used clinically: thioguanine, mercaptopurine, and azathioprine (a prodrug for mercaptopurine). All three agents have similar effects but are typically used for different indications. Thioguanine is most commonly used in the treatment of myeloid leukemias, mercaptopurine is used for lymphoid malignancies, and mercaptopurine and azathioprine are used for immune conditions.

Thiopurines are either activated to form TGNs (the major active metabolite) or deactivated by TPMT. Individuals who carry two non-functional TPMT alleles (“TPMT homozygotes”) universally experience life-threatening bone marrow suppression because of high levels of TGNs when treated with conventional doses. Individuals who carry one non-functional TPMT allele (“TPMT heterozygotes”) may also be unable to tolerate conventional doses of thiopurines due to increased levels of TGNs.

Drug: Azathioprine

Azathioprine is an immunosuppressive agent that is used in combination with other drugs to prevent the rejection of kidney transplants. It is also used in the management of active rheumatoid arthritis (1).

An off-label use of azathioprine is in the treatment of inflammatory bowel disease (IBD). Along with the closely related drug mercaptopurine (azathioprine is metabolized to mercaptopurine), azathioprine is used as an “immunomodulator” and as a “steroid-sparing agent” in the treatment of Crohn’s disease and ulcerative colitis (2).

Azathioprine is a slow-acting drug and for IBD, it typically takes at least three months of therapy before a therapeutic effect is observed. Therefore, azathioprine is used for the induction and maintenance of IBD remission rather than as a monotherapy for acute relapses (5). Because the discontinuation of azathioprine is associated with a high rate of relapse of IBD, azathioprine is usually continued long-term if there are no adverse effects (6, 7).

The use of azathioprine or the related drug mercaptourine has been associated with a 4-fold increased risk of developing lymphoma, which does not persist after discontinuation of therapy (8, 9).

The increased risk of malignancy led to the following boxed label on the FDA-approved drug label for azathioprine:

Malignancy: Patients receiving immunosuppressants, including azathioprine, are at increased risk of developing lymphoma and other malignancies, particularly of the skin. Physicians should inform patients of the risk of malignancy with azathioprine. As usual for patients with increased risk for skin cancer, exposure to sunlight and ultraviolet light should be limited by wearing protective clothing and using a sunscreen with a high protection factor (1).

Like all thiopurines, azathioprine is a purine analogue, and acts as an antimetabolite by interfering with nucleic acid synthesis and inhibiting purine metabolism. Azathioprine is first metabolized to mercaptopurine, which is then activated via HPRT1 (hypoxanthine phosphoribosyltransferase). This is followed by a series of reactions to form TGNs. The cytotoxicity of azathioprine is due, in part, to the incorporation of TGNs into DNA.

Inactivation of azathioprine occurs via two different pathways, via methylation (by TPMT) or via oxidation (by xanthine oxidase). TPMT activity is highly variable in patients because of genetic polymorphism in the TPMT gene.

One of the most frequent adverse reactions to azathioprine is myelosuppression, which can occur in any patient, and can usually be reversed by decreasing the dose of azathioprine. However, all patients who carry two nonfunctional TPMT alleles (approximately 0.3%) experience life-threatening myelosuppression after starting treatment with conventional doses of azathioprine due to high levels of TGNs.

Individuals who are heterozygous for nonfunctional TPMT alleles (approximately 10%) are at a significantly higher risk for toxicity than individuals with two functional alleles. However, some of these individuals, approximately 40–70%, can tolerate the full dose of azathioprine. This may be because heterozygous-deficient individuals have lower concentrations of less active metabolites, such as MeMPN (methylmercaptopurine nucleotides), than homozygous-deficient individuals (3, 4).

Approximately 90% of individuals have normal TPMT activity with two functional alleles; however, all individuals receiving azathioprine require close monitoring (3, 4, 10, 11). One study reports that in patients with IBD receiving thiopurine therapy, TPMT polymorphisms are associated with the overall incidence of adverse reactions and with bone marrow toxicity, but not with other adverse reactions, such as liver damage and pancreatitis. Therefore, although determining TPMT genotype is helpful before initiating therapy, regular blood tests to monitor for side effects are needed during therapy (12, 13).

The other azathioprine inactivation pathway is via oxidation, which is catalyzed by xanthine oxidase. If this pathway is inhibited, for example, in patients taking allopurinol (an inhibitor of xanthine oxidase), the decreased break down of azathioprine can lead to azathioprine toxicity (13). However, some studies have found that the co-administration of allopurinol, with a reduced dose of azathioprine (or mercaptopurine), can help optimize the treatment response in patients with IBD (14, 15).

Gene: TPMT

The TPMT gene encodes one of the important enzymes of phase II metabolism, thiopurine S-methyltransferase. TPMT is one of the main enzymes involved in the metabolism of thiopurines, such as azathioprine. TPMT activity is inherited as a co-dominant trait, as the TPMT gene is highly polymorphic with over 40 reported variant alleles (16-19).

The wild-type TPMT*1 allele is associated with normal enzyme activity. Individuals who are homozygous for TPMT*1 (TPMT normal metabolizers) are more likely to have a typical response to azathioprine and a lower risk of myelosuppression. This accounts for the majority of patients (~86–97%) (3, 4).

Individuals who are TPMT poor (approximately 0.3%) or intermediate (approximately 3–14%) metabolizers carry variant TPMT alleles that encode reduced or absent enzyme activity. Three variant TPMT alleles account for over 90% of the reduced or absent activity TPMT alleles (16, 17):

  • TPMT*2 (c.238G>C)
  • TPMT*3A (c.460G>A and c.719A>G)
  • TPMT*3B (c.460G>A)
  • TPMT*3C (c.719A>G)

The frequency of TPMT alleles varies among different populations. In the United States, the most common low-activity allele in the Caucasian population is TPMT*3A (~5%). This allele is also found in individuals who originate from India and Pakistan, but less frequently (18, 19).

In East Asian, African-American, and some African populations, the most common variant is TPMT*3C (~2%), although TPMT*8 may be more common in African populations than previously thought (~2%). In general, TPMT*2 occurs much less commonly, and TPMT*3B occurs rarely (18, 20).

Genetic Testing

Genetic testing is available for several TPMT variant alleles, which most commonly includes TPMT*2, *3A, and *3C as they account for >90% of inactivating alleles. Of note, rare and/or previously undiscovered variants will not be detected by variant-specific genotyping methods (3, 4, 21-24).

TPMT phenotype enzyme activity testing is also available by measuring TPMT activity in red blood cells directly. However, the results will not be accurate in patients who have received recent blood transfusions (13) and TPMT activity will also be falsely low in patients with leukemia, because of atypical hematopoiesis (25).

One study reported that TPMT genotyping was more reliable than phenotyping in identifying patients at risk of adverse reactions from thiopurine treatment (26). In addition, several studies report that the TPMT genotype is a better indicator than TPMT activity for predicting TGN accumulation or treatment outcome (11, 27-29).

Therapeutic Recommendations based on Genotype

This section contains excerpted1 information on gene-based dosing recommendations. Neither this section nor other parts of this review contain the complete recommendations from the sources.

2015 Statement from the US Food and Drug Administration (FDA): TPMT TESTING CANNOT SUBSTITUTE FOR COMPLETE BLOOD COUNT (CBC) MONITORING IN PATIENTS RECEIVING AZATHIOPRINE. TPMT genotyping or phenotyping can be used to identify patients with absent or reduced TPMT activity. Patients with low or absent TPMT activity are at an increased risk of developing severe, life threatening myelotoxicity from azathioprine if conventional doses are given. Physicians may consider alternative therapies for patients who have low or absent TPMT activity (homozygous for non-functional alleles). Azathioprine should be administered with caution to patients having one non-functional allele (heterozygous) who are at risk for reduced TPMT activity that may lead to toxicity if conventional doses are given. Dosage reduction is recommended in patients with reduced TPMT activity. Early drug discontinuation may be considered in patients with abnormal CBC results that do not respond to dose reduction.

Please review the complete therapeutic recommendations that are located here: (1).

2013 Statement from the Clinical Pharmacogenetics Implementation Consortium (CPIC): Testing for TPMT status is recommended prior to starting azathioprine therapy so that the starting dosages can be adjusted accordingly—see Table 1 for dosing recommendations. In homozygous variant individuals, either an alternative agent should be used, or the doses of azathioprine should be drastically reduced. In heterozygous individuals, depending on the disease being treated, starting doses should be reduced. In both patient groups, a longer period of time should be left after each dose adjustment to allow for a steady state to be reached.

Please review the complete therapeutic recommendations that are located here: (3, 4).

Nomenclature

Common allele nameAlternative namesHGVS reference sequencedbSNP reference identifier for allele location
CodingProtein
TPMT*2238G>C
Ala80Pro
NM_000367.2:c.238G>CNP_000358.1:p.Ala80Prors1800462
TPMT*3AThis allele contains two variants in cis: c.460G>A and c.719A>G
TPMT*3B460G>A
Ala154Thr
NM_000367.2:c.460G>ANP_000358.1:p.Ala154Thrrs1800460
TPMT*3C719A>G
Tyr240Cys
NM_000367.2:c.719A>GNP_000358.1:p.Tyr240Cysrs1142345

The TPMT Nomenclature Committee defines the nomenclature and numbering of novel TPMT variants: http://www.imh.liu.se/tpmtalleles

Guidelines for the description and nomenclature of gene variations are available from the Human Genome Variation Society (HGVS): http://www.hgvs.org/content/guidelines

Acknowledgments

The author would like to thank Stuart A. Scott, Assistant Professor of Genetics and Genomic Sciences, Icahn School of Medicine at Mount Sinai; for reviewing this summary.

First edition:

The author would like to thank:

The Pharmacogenomics Knowledgebase: http://www.pharmgkb.org

The Clinical Pharmacogenetics Implementation Consortium: http://www.pharmgkb.org/page/cpic

Version History

To view an earlier version of this summary (Update: March 18, 2013), please click here.

References

1.
AZATHIOPRINE- azathioprine tablet [package insert]. Mahwah, NJ: Glenmark Pharmaceuticals Inc.; 2015. Available from: http://dailymed​.nlm.nih​.gov/dailymed/drugInfo​.cfm?setid=ceab8e8b-d022-4d0c-a552-cc5782446248.
2.
PharmGKB [Internet]. Palo Alto (CA): Stanford University. Chemical: Drug - azathioprine [Cited 2016 January 12]. Available from: https://www​.pharmgkb​.org/chemical/PA448515.
3.
Relling M.V., Gardner E.E., Sandborn W.J., Schmiegelow K., et al. Clinical Pharmacogenetics Implementation Consortium guidelines for thiopurine methyltransferase genotype and thiopurine dosing. Clinical pharmacology and therapeutics. 2011;89(3):387–91. [PMC free article: PMC3098761] [PubMed: 21270794]
4.
Relling M.V., Gardner E.E., Sandborn W.J., Schmiegelow K., et al. Clinical pharmacogenetics implementation consortium guidelines for thiopurine methyltransferase genotype and thiopurine dosing: 2013 update. Clin Pharmacol Ther. 2013;93(4):324–5. [PMC free article: PMC3604643] [PubMed: 23422873]
5.
Prefontaine E., Macdonald J.K., Sutherland L.R. Azathioprine or 6-mercaptopurine for induction of remission in Crohn's disease. Cochrane Database Syst Rev. 2009;(4):CD000545. [PubMed: 19821270]
6.
Vilien M., Dahlerup J.F., Munck L.K., Norregaard P., et al. Randomized controlled azathioprine withdrawal after more than two years treatment in Crohn's disease: increased relapse rate the following year. Aliment Pharmacol Ther. 2004;19(11):1147–52. [PubMed: 15153167]
7.
Treton X., Bouhnik Y., Mary J.Y., Colombel J.F., et al. Azathioprine withdrawal in patients with Crohn's disease maintained on prolonged remission: a high risk of relapse. Clin Gastroenterol Hepatol. 2009;7(1):80–5. [PubMed: 18849016]
8.
Kotlyar, D.S., J.D. Lewis, L. Beaugerie, A. Tierney, et al., Risk of lymphoma in patients with inflammatory bowel disease treated with azathioprine and 6-mercaptopurine: a meta-analysis. Clin Gastroenterol Hepatol, 2015. 13(5): p. 847-58 e4; quiz e48-50. [PubMed: 24879926]
9.
Khan, N., A.M. Abbas, G.R. Lichtenstein, E.V. Loftus, Jr., et al., Risk of lymphoma in patients with ulcerative colitis treated with thiopurines: a nationwide retrospective cohort study. Gastroenterology, 2013. 145(5): p. 1007-1015 e3. [PubMed: 23891975]
10.
DiPiero J., Teng K., Hicks J.K. Should thiopurine methyltransferase (TPMT) activity be determined before prescribing azathioprine, mercaptopurine, or thioguanine? Cleve Clin J Med. 2015;82(7):409–13. [PubMed: 26185939]
11.
Lennard L., Cartwright C.S., Wade R., Vora A. Thiopurine dose intensity and treatment outcome in childhood lymphoblastic leukaemia: the influence of thiopurine methyltransferase pharmacogenetics. Br J Haematol. 2015;169(2):228–40. [PMC free article: PMC4737107] [PubMed: 25441457]
12.
Liu Y.P., Wu H.Y., Yang X., Xu H.Q., et al. Association between thiopurine S-methyltransferase polymorphisms and thiopurine-induced adverse drug reactions in patients with inflammatory bowel disease: a meta-analysis. PLoS One. 2015;10(3):e0121745. [PMC free article: PMC4370632] [PubMed: 25799415]
13.
MERCAPTOPURINE- mercaptopurine tablet [package insert]. Spring Valley, NY: Par Phamaceutical Companies; 2015. Available from: http://dailymed​.nlm.nih​.gov/dailymed/drugInfo​.cfm?setid=40b09616-5bb1-4ef8-98cd-d87537254296.
14.
Smith M.A., Blaker P., Marinaki A.M., Anderson S.H., et al. Optimising outcome on thiopurines in inflammatory bowel disease by co-prescription of allopurinol. J Crohns Colitis. 2012;6(9):905–12. [PubMed: 22386736]
15.
Goel R.M., Blaker P., Mentzer A., Fong S.C., et al. Optimizing the use of thiopurines in inflammatory bowel disease. Ther Adv Chronic Dis. 2015;6(3):138–46. [PMC free article: PMC4416969] [PubMed: 25954498]
16.
McLeod H.L., Siva C. The thiopurine S-methyltransferase gene locus -- implications for clinical pharmacogenomics. Pharmacogenomics. 2002;3(1):89–98. [PubMed: 11966406]
17.
PharmGKB [Internet]. Palo Alto (CA): Stanford University. Gene: TPMT thiopurine S-methyltransferase (TPMT). [Cited 2016 January 11]. Available from: https://www​.pharmgkb.org/gene/PA356.
18.
Wang L., Pelleymounter L., Weinshilboum R., Johnson J.A., et al. Very important pharmacogene summary: thiopurine S-methyltransferase. Pharmacogenetics and genomics. 2010;20(6):401–5. [PMC free article: PMC3086840] [PubMed: 20154640]
19.
PharmGKB [Internet]. Palo Alto (CA): Stanford University. Haplotype TPMT *3A. [Cited 2016 Apr 28]. Available from: http://www​.pharmgkb.org​/haplotype/PA165819270.
20.
Tai H.L., Krynetski E.Y., Yates C.R., Loennechen T., et al. Thiopurine S-methyltransferase deficiency: two nucleotide transitions define the most prevalent mutant allele associated with loss of catalytic activity in Caucasians. American journal of human genetics. 1996;58(4):694–702. [PMC free article: PMC1914689] [PubMed: 8644731]
21.
Roberts R.L., Wallace M.C., Drake J.M., Stamp L.K. Identification of a novel thiopurine S-methyltransferase allele (TPMT*37). Pharmacogenet Genomics. 2014;24(6):320–3. [PubMed: 24710034]
22.
Appell M.L., Berg J., Duley J., Evans W.E., et al. Nomenclature for alleles of the thiopurine methyltransferase gene. Pharmacogenet Genomics. 2013;23(4):242–8. [PMC free article: PMC3727893] [PubMed: 23407052]
23.
Landy J., Bhuva N., Marinaki A., Mawdsley J. Novel thiopurine methyltransferase variant TPMT*28 results in a misdiagnosis of TPMT deficiency. Inflamm Bowel Dis. 2011;17(6):1441–2. [PubMed: 20945351]
24.
Matimba A., Li F., Livshits A., Cartwright C.S., et al. Thiopurine pharmacogenomics: association of SNPs with clinical response and functional validation of candidate genes. Pharmacogenomics. 2014;15(4):433–47. [PMC free article: PMC4027966] [PubMed: 24624911]
25.
Lennard L., Chew T.S., Lilleyman J.S. Human thiopurine methyltransferase activity varies with red blood cell age. Br J Clin Pharmacol. 2001;52(5):539–46. [PMC free article: PMC2014613] [PubMed: 11736862]
26.
Hindorf U., Appell M.L. Genotyping should be considered the primary choice for pre-treatment evaluation of thiopurine methyltransferase function. J Crohns Colitis. 2012;6(6):655–9. [PubMed: 22398041]
27.
Gonzalez-Lama Y., Bermejo F., Lopez-Sanroman A., Garcia-Sanchez V., et al. Thiopurine methyl-transferase activity and azathioprine metabolite concentrations do not predict clinical outcome in thiopurine-treated inflammatory bowel disease patients. Aliment Pharmacol Ther. 2011;34(5):544–54. [PubMed: 21722149]
28.
Lennard L., Cartwright C.S., Wade R., Richards S.M., et al. Thiopurine methyltransferase genotype-phenotype discordance and thiopurine active metabolite formation in childhood acute lymphoblastic leukaemia. Br J Clin Pharmacol. 2013;76(1):125–36. [PMC free article: PMC3703235] [PubMed: 23252716]
29.
Konidari A., Anagnostopoulos A., Bonnett L.J., Pirmohamed M., et al. Thiopurine monitoring in children with inflammatory bowel disease: a systematic review. Br J Clin Pharmacol. 2014;78(3):467–76. [PMC free article: PMC4243898] [PubMed: 24592889]

Footnotes

1

The FDA labels specific drug formulations. We have substituted the generic names for any drug labels in this excerpt. The FDA may not have labelled all formulations containing the generic drug.

Copyright Notice

All Medical Genetics Summaries content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 International (CC BY 4.0) license which permits copying, distribution, and adaptation of the work, provided the original work is properly cited and any changes from the original work are properly indicated. Any altered, transformed, or adapted form of the work may only be distributed under the same or similar license to this one.

Bookshelf ID: NBK100661PMID: 28520349

Views

Tests in GTR by Condition

Tests in GTR by Gene

Related information

  • MedGen
    Related information in MedGen
  • PMC
    PubMed Central citations
  • PubMed
    Links to PubMed

Similar articles in PubMed

See reviews...See all...

Recent Activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...